Tarsus Pharmaceuticals
TARS
73.01
-4.66
-6.00%
Tarsus Pharmaceuticals
US · TARS
#2389 by market cap
Listed 2020
73.01
-4.66
-6.00%
Periodic snapshot; not a real-time feed.
· 2026-11-20 20:02
Quant vs Street three independent views, side by side
StockVane factor grade
B
Momentum strategy signal
Sell
Analyst consensus
Buy
Mostly aligned, one view stands apart.
Not investment advice. The factor grade ranks this stock on fundamentals against StockVane's covered universe; the momentum strategy signal is a rules-based backtest, not a recommendation; analyst consensus reflects sell-side coverage. The three use different methods and can reasonably disagree.
✦ Quant Analyst Revision Trend how this is computed
Mixed
1
■ Upgrades■ Downgrades
- 1 upgrade vs 0 downgrades among tracked analyst rating changes.
- Most recent: Goldman Sachs moved from Hold to Buy on 2026-09-24.
Analyst consensus 8 analysts
Buy
Avg price target 105.57 +44.6%
Price target rangecurrent 73.01
Low97.00
Avg105.57
High116.00
Buy 100%
Hold 0%
Sell 0%
Recent ratings (25)
| Date | Firm | Analyst | Rating | Target |
|---|---|---|---|---|
| 2026-11-11 | Barclays | -- | Buy | 110.00 |
| 2026-11-06 | Mizuho Securities | -- | Buy | 102.00 |
| 2026-11-04 | BofA Securities | -- | Buy | -- |
| 2026-11-04 | Guggenheim | -- | Buy | 97.00 |
| 2026-11-04 | H.C. Wainwright | -- | Buy | 106.00 |
| 2026-11-04 | Oppenheimer | -- | Buy | 103.00 |
| 2026-10-29 | Mizuho Securities | -- | Buy | 94.00 |
| 2026-10-12 | BofA Securities | -- | Buy | 84.00 |
| 2026-10-09 | Barclays | -- | Buy | 110.00 |
| 2026-10-02 | Oppenheimer | -- | Buy | 100.00 |
| 2026-09-24 | Goldman Sachs | -- | Buy | 116.00 |
| 2026-09-16 | Barclays | -- | Buy | 110.00 |
| 2026-09-08 | Jefferies | -- | Buy | 105.00 |
| 2026-08-12 | William Blair | -- | Buy | -- |
| 2026-08-12 | Oppenheimer | -- | Buy | 100.00 |
| 2026-08-11 | Mizuho Securities | -- | Buy | 100.00 |
| 2026-08-08 | LifeSci Capital | -- | Buy | 104.00 |
| 2026-08-07 | LifeSci Capital | -- | Buy | 104.00 |
| 2026-08-07 | Mizuho Securities | -- | Buy | 100.00 |
| 2026-08-07 | H.C. Wainwright | -- | Buy | 88.00 |
| 2026-08-04 | Mizuho Securities | -- | Buy | 98.00 |
| 2026-07-31 | Mizuho Securities | -- | Buy | 98.00 |
| 2026-07-21 | Guggenheim | -- | Buy | 89.00 |
| 2026-07-21 | Oppenheimer | -- | Buy | 97.00 |
| 2026-07-14 | William Blair | -- | Buy | -- |
Price target trend monthly average, last 3 years
Recent rating changes
| Date | Firm | Change | Target |
|---|---|---|---|
| 2026-09-24 | Goldman Sachs | Hold → Buy | 116.00 |
Earnings history price reaction on the day
| Period | Report date | Session | Options expected | Actual move |
|---|---|---|---|---|
| 2026/Q3 | 2026-11-03 | -- | ±13.75% | -0.93% (in line) |
| 2026/Q2 | 2026-08-06 | -- | ±11.25% | +6.59% (in line) |
| 2026/Q1 | 2026-05-06 | After close | ±13.47% | -1.24% (in line) |
| 2025/Q4 | 2026-02-23 | After close | ±14.71% | +7.79% (in line) |
| 2025/Q3 | 2025-11-04 | After close | ±12.86% | -4.62% (in line) |
| 2025/Q2 | 2025-08-06 | After close | ±17.32% | +15.15% (in line) |
| 2025/Q1 | 2025-05-01 | After close | ±14.67% | -5.84% (in line) |
| 2024/Q4 | 2025-02-25 | -- | ±16.97% | -9.33% (in line) |
| 2024/Q3 | 2024-11-13 | After close | ±23.27% | +0.31% (in line) |
| 2024/Q2 | 2024-08-08 | After close | ±16.52% | +13.72% (in line) |
| 2024/Q1 | 2024-05-08 | After close | ±18.63% | -8.86% (in line) |
| 2023/Q4 | 2024-02-27 | -- | ±14.92% | -3.44% (in line) |
"Options expected" is the pre-earnings options market's implied move (a straddle-style estimate), shown next to what actually happened.
Quote time 2026-11-20 20:02:22 · For reference only, not investment advice and not tailored to your situation.
Tarsus Pharmaceuticals discussion 0 comments